 This is a single-arm, open-label phase III study designed to define the toxicity profile, pharmacokinetic PK profile, and anti-tumor activity of a multi-dose regimen of SGN-30 in patients with refractory or recurrent CD30 hematologic malignancies. The phase I study will be a modified dose escalation of SGN-30. Based on preclinical pharmacology and toxicokinetics TK and the first use in human single-dose phase I study, SGN-30 will be administered on a weekly schedule. An initial dose of 2 mgkg will escalate until the maximum tolerated dose MTD has been reached or until a weekly dose of 12 mgkg is achieved. 